FY2023 · ended Dec 31, 2023 · Revenue $0 · Filed Apr 8, 2025
Hepion Pharmaceuticals, Inc. (HEPA) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue (TTM)
$0
Net income (TTM)
$-38.52M
+20.6% vs year-ago TTM
Operating cash flow (TTM)
$-1.59M
+74.1% vs year-ago TTM
Free cash flow
$-40.90M
-16.9% vs prior year
EPS (TTM)
$46.68
+466.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
11.62M
+5.9% vs prior year
Net cash
$1.83M
FY 2025
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HEPA (OTC), CTRVP (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Red Bank, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1583771
- Former names
- ContraVir Pharmaceuticals, Inc. (until Jul 23, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 |
| Operating income | -$4.2M | -$19.3M | -$48.4M | -$45.5M | -$30.4M |
| Net income | -$8.3M | -$13.2M | -$48.9M | -$42.2M | -$32.7M |
| Diluted EPS | -$0.88 | -$107.35 | -$616.07 | -$11.90 | -$0.47 |
| Operating cash flow | -$3.3M | -$18.2M | -$40.9M | -$35.0M | -$31.2M |
| Free cash flow | — | — | -$40.9M | -$35.0M | -$31.4M |
| Total assets | $3.1M | $1.6M | $18.1M | $60.2M | $103.6M |
| Total liabilities | $402,405 | $3.5M | $10.8M | $10.4M | $10.6M |
| Stockholders' equity | $2.7M | -$1.9M | $7.3M | $49.9M | $93.0M |
| Cash and investments | $1.8M | $406,408 | $14.8M | $51.2M | $91.3M |
| Total debt | $0 | — | $209,020 | $53,614 | $316,992 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Officer or director change
|
Oct 9, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 2, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Auditor change
|
Sep 28, 2026 | Sep 21, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Sep 8, 2026 | Sep 3, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Aug 27, 2026 | Aug 25, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 20, 2026 | Aug 19, 2026 |
All 723 Hepion Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.